Today, a Director at VolitionRX (VNRX), Martin Charles Faulkes, bought shares of VNRX for $213.6K.
This recent transaction increases Martin Charles Faulkes’ holding in the company by 4.14% to a total of $5.48 million.
See today’s analyst top recommended stocks >>
Currently, VolitionRX has an average volume of 35.56K. The Company has a Price to Book ratio of 7.7075.
Starting in July 2018, VNRX received 15 Buy ratings in a row.
Company insider trades’ information is brought to you by the DailyInsider, a proprietary algorithm that analyzes insider trading activity to detect the most attractive trading opportunities. To subscribe to the DailyInsider visit this page.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
VolitionRX Ltd. is a multi-national life sciences company. It engages in the development of blood-based cancer tests to help diagnose a range of cancers. Its products include the Nucleosomics platform that identifies and measures nucleosomes in the bloodstream or other bodily fluid. The company was founded on August 5, 2010 and is headquartered in Singapore.
